Eyeworld Daily News

JULY 23, 2021 | EYEWORLD DAILY NEWS | 25 ASCRS ANNUAL MEETING DAILY NEWS with about 300 participants in combination with cataract surgery. A second standalone trial will be coming soon. The procedure, she said, is suited for both subspecialists and non-subspecialists and is an adoptable laser-based tool for glaucoma patients with a smooth learning curve. John Berdahl, MD, presented on behalf of Equinox, noting that a safer treatment for the toughest glaucoma is needed. Eye pressure goes up at night, and blood pressure goes down, he said; lower IOP at night can help slow progression of glaucoma. He spoke about the Multi-Pressure Dial, the first non-surgical, non-pharmacologic connected care option for glau- coma. It treats normal tension glaucoma and severe primary open-angle glaucoma, preventing those who are most at risk from going blind. It predictably and precisely lowers IOP and has a low risk of complications. The treatment controls pressure at its most vulnerable time, Dr. Berdahl said, and features remote patient monitoring. Hadi Srass presented for ViaLase, noting the challenges facing the surgical management of glaucoma, including providing a long-lasting IOP reduction for all patients, being a non-inva- sive treatment with no surgical trauma, allowing future repeated treatment, minimizing postopera- tive care, eliminating the need for topical medications, and shorten- ing recovery time. The ViaLase solution is a µ-OCT image-guided femtosec- ond laser trabeculostomy. It's a novel technology to reduce IOP by increasing aqueous outflow using a micron resolution, 3D im- age-guided femtosecond laser to non-invasively create customized drainage channels through the trabecular meshwork in the vicini- ty of collector channels, he said. He noted results from its first clinical trial performed in Hungary, which included 22 eyes and focused on safety. There was excellent IOP reduction through 6 months, he said, and results compared favorably to other tra- becular outflow technologies. New glaucoma treatments featured at Eyecelerator N athan Radcliffe, MD, and Thomas Samuelson, MD, moderated the session on new glaucoma treatments, with panelists Ron Bache, Leon Herndon, MD, Sarah Van Tassel, MD, and Robert Warner. Rui Jing Jiang presented on behalf of Avisi Technologies, sharing information about the company's VisiPlate, an ultrathin, multichannel aqueous shunt for glaucoma designed to avoid occlu- sion. The shunt, she said, initially targets moderate to severe glau- coma patients. It avoids occlusion with non-fibrotic materials, a multichannel design that creates outflow redundancy, and a sur- face area that maintains drainage space. She said that its unique design helps maintain lower IOP over time and helps overcome trade-offs in efficacy and safety compared to other treatments. It's the only device with redundant, multiple outflow pathways to avoid occlusion; it can maintain the drainage space to sustain IOPs over time; and non-fibrotic mate- rials avoid failure from scarring. She noted the commencement of the first in-human clinical trial. Matilda Parente, MD, dis- cussed ELT Sight's ELIOS procedure, a specialized excimer laser system with a tissue-sparing angle-based technique that helps restore outflow with no device left behind. The procedure is being used in Europe with CE mark approval. In March, Dr. Parente said, the company got the green light from the FDA to begin a clinical trial Mr. Bache, Dr. Herndon, Dr. Van Tassel, Mr. Warner, and Dr. Radcliffe listen to presentations on new glaucoma treatments during the Eyecelerator program. Source: ASCRS

• Cover